建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
The Company's 2022Q1 consolidated financial statements have been approved by the Board of Directors
Oneness received the notification by the international CRO on the unblinded data of FB825 Phase 2a study in moderate-to-severe atopic dermatitis in the U.S.
News-Oneness Ranked among Top 5% in the 8th Corporate Governance Evaluation
The Food and Drug Administration–Philippines (PFDA) has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon
Oneness Biotech has been invited to present at the "11th Taiwan CEO Week" online investor's conference co-organized by TWSE and QIC
Oneness Biotech Co., Ltd. receives ISO13485 Medical Devices Quality Management System Certificate.
Oneness re-announces the Board of Directors resolved to convene the Annual Shareholders' Meeting of 2022.(Method of convening the meeting: hybrid shareholders' meeting)
Oneness announces the information about the investor's conference of 2022 Q1.
Oneness Biotech Co., Ltd. receives an Indonesian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).
The Board of Directors resolved not to distribute dividends.
Oneness Nanchou manufacturing site received GMP certificate from the FDA Philippines
Oneness re-announces the Board of Directors resolved to convene the Annual Shareholders' Meeting of 2022.
The Company's 2021 consolidated financial statements have been approved by the Board of Directors
Oneness Biotech has been invited to present at the "2022 APAC TMT Conference" organized by BofA Securities.
Oneness Biotech Co., Ltd. received an India patent on FB704A, an anti-IL6 fully-human antibody new drug.
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?